Gilead Sciences Inc. (GILD)

67.39
0.14 0.21
NASDAQ : Health Technology
Prev Close 67.53
Open 67.65
Day Low/High 67.00 / 67.93
52 Wk Low/High 63.76 / 89.54
Volume 4.49M
Avg Volume 7.15M
Exchange NASDAQ
Shares Outstanding 1.30B
Market Cap 87.94B
EPS 3.50
P/E Ratio 25.63
Div & Yield 2.28 (3.14%)

Latest News

Kite Announces New Worldwide Facilities And Expanded Collaboration With National Cancer Institute To Support Cell Therapy Pipeline

Kite Announces New Worldwide Facilities And Expanded Collaboration With National Cancer Institute To Support Cell Therapy Pipeline

Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe.

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

Gilead Sciences Becomes #41 Most Shorted Nasdaq 100 Component, Replacing Lam Research

The most recent short interest data has been released for the 04/30/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Harish Manwani Joins Gilead Sciences' Board Of Directors

Harish Manwani Joins Gilead Sciences' Board Of Directors

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Harish M.

Gilead Sciences To Present At The Bank Of America Merrill Lynch Healthcare Conference On Wednesday, May 16

Gilead Sciences To Present At The Bank Of America Merrill Lynch Healthcare Conference On Wednesday, May 16

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Gilead Sciences Announces Second Quarter 2018 Dividend

Gilead Sciences Announces Second Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces First Quarter 2018 Financial Results

Gilead Sciences Announces First Quarter 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2018.

Are Apple's Best Days in the Past?: Market Recon

Are Apple's Best Days in the Past?: Market Recon

I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.

Gilead And Verily Announce Scientific Collaboration To Identify And Understand Immunological And Molecular Drivers Of Inflammatory Diseases

Gilead And Verily Announce Scientific Collaboration To Identify And Understand Immunological And Molecular Drivers Of Inflammatory Diseases

Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily's Immunoscape platform to identify and better understand the immunological basis of three common and serious...

European CHMP Adopts Positive Opinion For Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

European CHMP Adopts Positive Opinion For Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization...

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Why Uber's Self-Driving Car Fatality Won't End Autonomous Driving

Why Uber's Self-Driving Car Fatality Won't End Autonomous Driving

The fatality that came at the hands of a self-driving Uber vehicle was tragic. But keep in mind, self-driving cars will be safer than human drivers in the not-too-distant future.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Gilead Sciences' Norbert Bischofberger, PhD, To Step Down; John McHutchison, MD, Appointed Chief Scientific Officer And Andrew Cheng, MD, PhD, Appointed Chief Medical Officer

Gilead Sciences' Norbert Bischofberger, PhD, To Step Down; John McHutchison, MD, Appointed Chief Scientific Officer And Andrew Cheng, MD, PhD, Appointed Chief Medical Officer

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at...

Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched To Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) From A Boosted Protease Inhibitor-Based Regimen Or Boosted Elvitegravir-Containing Regimen

Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched To Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) From A Boosted Protease Inhibitor-Based Regimen Or Boosted Elvitegravir-Containing Regimen

Gilead Sciences, Inc. (NASDAQ: GILD) today announced 48-week results from a Phase 3 study (Study 1961) of 470 virologically suppressed adult women with HIV infection, evaluating the efficacy and safety of switching from a...

Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched To Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) From Regimen Containing Abacavir, Dolutegravir And Lamivudine

Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched To Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) From Regimen Containing Abacavir, Dolutegravir And Lamivudine

Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from a Phase 3 study (Study 1844) evaluating the efficacy and safety of switching from a regimen containing abacavir, dolutegravir and lamivudine...

Gilead Announces Data From New Preclinical Study Evaluating A Combination Of An Investigational TLR7 Agonist And An Investigational HIV Envelope Targeting Antibody In SHIV-Infected, Virally Suppressed Monkeys

Gilead Announces Data From New Preclinical Study Evaluating A Combination Of An Investigational TLR7 Agonist And An Investigational HIV Envelope Targeting Antibody In SHIV-Infected, Virally Suppressed Monkeys

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating the combination of a proprietary...

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?

Gilead Sciences Announces Senior Management Change

Gilead Sciences Announces Senior Management Change

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that James Meyers, Executive Vice President, Commercial Operations, will retire.

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --

TheStreet Quant Rating: C (Hold)